One Health Co.'s flagship product, FidoCure, uses genomic testing to identify possible cancer-causing mutations in dogs and recommends personalized therapeutic treatments. The service provides veterinarians guidance in selecting from 14 human-grade therapies for oncology patients. One Health reported FidoCure is available through more than 200 U.S. veterinarians and has been adopted by over 25% of practicing veterinary oncologists in the United States. The company said the $10 million raise will be used to accelerate the expansion of FidoCure. CEO and co-founder Christina Lopes framed the effort as bringing FDA‑approved human precision‑medicine diagnostics and treatments into canine cancer care while building data to advance human oncology research. One Health is based in Palo Alto, California.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2020